What country has the most dogs?

What country has the most dogs?

Kevisaurus is correct. The US has the most dogs. Estimates vary from 46 million to 61 million according to various sources on the Internet. That also gives the US the highest dog ownership rate in the world. According to the American Vetinerary Medical Association, 37.2 per cent of US households owned a dog in 2007.

However, Kevisaurus not quite on the mark re China. Brazil has the second highest number of dogs (around 30 million). China only has around 20 million dogs (maybe that's because more are eaten than are kept as pets).

A country with a dog ownership rate almost as high as the US is South Africa (maybe that's because they need them there as guard dogs more than as pets)

.

Study shows dog-loving Ireland hates cats

That cat may try to look all cute and Irish, but in Ireland, the dog will always win out

The Irish love their dogs, but aren’t a big fan of cats, according to a new study about pet ownership in Ireland.

Research by University College Dublin (UCD) found that 36 percent of homes in Ireland have a dog, while just one in 10 homes own a cat.

The dog-to-cat ratio is much more drastic than in most other countries. For instance, in the U.S., 37 percent of homes have dogs while 32 percent have cats, while in Britain, the split is even smaller with 22 percent dogs and 18 percent cats.

But Ireland is unequivocally a nation of dog lovers.

Researchers believe the Irish bias towards dogs may be linked to the significance and prevalence of farming and rural life in Ireland, and the fact that many more Irish citizens live in spacious houses, rather than small apartments. The study also states that in Ireland, dogs are viewed as pets while cats are largely considered stray animals.

The Mars company, which manufactures Pedigree dog food and Whiskas cat products, confirmed the trend, saying: “Ireland is unique in Europe. Other countries are much more cat-loving. We tend to have houses as opposed to apartments, so we have the space to look after dogs while cats are more conducive to apartment-living, which is how people are more likely to live on the continent.”

Tony Forshaw of the Siamese and All Breeds Cat Club of Ireland told the Times that there isn’t a history of owning cats in Ireland, compared with the U.S. or Britain, and that “Irish people tend to laugh at cats.”

Forshaw blames the Irish dog bias on the fact that man’s best friend gets more screen time in movies and TV.

“On films and television you’ll always see people with dogs, you rarely see cats,” he said. “But after that advert on television with the hairless sphinx cat there was a huge amount of people ringing up looking for one of them. When people see cats in a popular context, they do go looking for them.”

Apparently not all Irish people are laughing at felines – the UCD study confirmed the stereotype most cat owners are elderly women.

Research shows that Irish cat owners are 1.5 times more likely to be female, and that those aged 55 to 64 were more than twice as likely to own a cat than 18 to 24-year-olds.

Martin Downes of the UCD Veterinary Science Center told the Times: “Older women are more likely to own cats than anyone else. It’s probably for companionship and it’s a lot easier to manage a cat because you don’t have to walk it every day.”

Vaccination Schedule for Dogs

A possible vaccination schedule for the "average" dog is shown below.

Age	Vaccination
5 weeks	Parvovirus: For puppies at high risk. Check with your veterinarian.
6 & 9 weeks	Combination vaccine* without leptospirosis.Coronavirus: where coronavirus is a concern.
12 weeks or older	Rabies: Given by your local veterinarian (age at vaccination may vary according to local law).
12 & 15 weeks**	Combination vaccine*Leptospirosis: include leptospirosis in the combination vaccine where leptospirosis is a concern, or if traveling to an area where it occurs. Coronavirus: where coronavirus is a concern. Lyme: where Lyme disease is a concern or if traveling to an area where it occurs.
Adult	Combination vaccine*Leptospirosis: include leptospirosis in the combination vaccine where leptospirosis is a concern, or if traveling to an area where it occurs. Coronavirus: where coronavirus is a concern. Lyme: where Lyme disease is a concern or if traveling to an area where it occurs. Rabies: Given by your local veterinarian (time interval between vaccinations may vary according to local law).
Recommendations vary depending on the age, breed, and health status of the dog, the potential of the dog to be exposed to the disease, the type of vaccine, whether the dog is used for breeding, and the geographical area where the dog lives or may visit. *A combination vaccine, often called a 5-way vaccine, usually includes adenovirus cough and hepatitis, canine distemper, parainfluenza, and parvovirus. Some combination vaccines may also include leptospirosis (7-way vaccines) and/or coronavirus. The inclusion of either canine adenovirus-1 or adenovirus-2 in a vaccine will protect against both adenovirus cough and hepatitis; adenovirus-2 is highly preferred. **Some puppies may need additional vaccinations against parvovirus after 15 weeks of age. Consult with your local veterinarian. Bordetella and parainfluenza: For complete canine cough protection, we recommend Intra-Trac III ADT. For dogs that are shown, in field trials, or are boarded, we recommend vaccination every six to twelve months with Intra-Trac III ADT.

Canine and Feline Vaccination Guidelines

UC Davis VMTH Canine and Feline Vaccination Guidelines (Revised 11/09)

The UC Davis VMTH vaccination guidelines below have been based on recently published studies and recommendations made by task forces (including the AAFP/AFM Advisory Panel on Feline Vaccines, AAHA Canine Vaccine Task Force, and the AVMA Council on Biologic and Therapeutic Agents), which include representatives from academia, private practices, governmental regulatory bodies, and industry. These groups have evaluated the benefits versus risks of the vaccines currently available on the market. Interested readers are referred to documents published by these groups for further information (see References and Resources listed at the end of this document). The document below has been generated by a group of faculty and staff at UC Davis School of Veterinary Medicine for the purposes of VMTH veterinary student education and as a reference for referring veterinarians. These are only general guidelines, as the vaccine types recommended and the frequency of vaccination vary depending on the lifestyle of the pet being vaccinated, i.e. indoor vs outdoor pets, travel plans, kennel/boarding plans, and underlying disease conditions such as immune-mediated diseases or pre-existing infections such as FIV infection. Because these factors may change over time, we recommend the vaccination plan for each individual pet be decided by the owner at routine annual examinations, following a discussion between the veterinarian and the client regarding the animal's lifestyle in the year ahead. Guidelines for vaccination in shelter situations can be accessed at the Center for Companion Animal Health's shelter medicine website. A previous history of vaccination reactions in an individual pet will also affect recommendations for vaccination. For all vaccines given, the product, expiration date, lot number, route and location of injection is documented in the record.

It should also be noted that much research in the area of companion animal vaccinology is required to generate optimal recommendations for vaccination of dogs and cats. As further research is performed, and as new vaccines become available on the market, this document will be continuously updated and modified.

Canine Vaccination Guidelines

Canine Core Vaccines

Core vaccines are recommended for all puppies and dogs with an unknown vaccination history. The diseases involved have significant morbidity and mortality and are widely distributed, and in general, vaccination results in relatively good protection from disease. These include vaccines for canine parvovirus (CPV), canine distemper virus (CDV), canine adenovirus (CAV), and rabies.

Canine Parvovirus, Distemper Virus, and Adenovirus-2 Vaccines

For initial puppy vaccination (≤ 16 weeks), one dose of vaccine containing modified live virus (MLV) CPV, CDV, and CAV-2 is recommended every 3-4 weeks from 6-8 weeks of age, with the final booster being given no sooner than 16 weeks of age. For dogs older than 16 weeks of age, two doses of vaccine containing modified live virus (MLV) CPV, CDV, and CAV-2 given 3-4 weeks apart are recommended. After a booster at one year, revaccination is recommended every 3 years thereafter, ideally using a product approved for 3-year administration, unless there are special circumstances that warrant more or less frequent revaccination. Note that recommendations for killed parvovirus vaccines and recombinant CDV vaccines are different from the above. These vaccines are not currently stocked by our pharmacy or routinely used at the VMTH. We do not recommend vaccination with CAV-1 vaccines, since vaccination with CAV-2 results in immunity to CAV-1, and the use of CAV-2 vaccines results in less frequent adverse events.

Canine Rabies Virus Vaccines

In accordance with California state law, we recommend that puppies receive a single dose of killed rabies vaccine at 16 weeks of age. Adult dogs with unknown vaccination history should also receive a single dose of killed rabies vaccine. A booster is required one year later, and thereafter, rabies vaccination should be performed every 3 years using a vaccine approved for 3-year administration.

Canine Non-Core Vaccines

Non-core vaccines are optional vaccines that should be considered in light of the exposure risk of the animal, ie. based on geographic distribution and the lifestyle of the pet. Several of the diseases involved are often self-limiting or respond readily to treatment. Vaccines considered as non-core vaccines are canine parainfluenza virus (CPiV), canine influenza virus, distemper-measles combination vaccine, Bordetella bronchiseptica, Leptospira spp., and Borrelia burgdorferi. Vaccination with these vaccines is generally less effective in protecting against disease than vaccination with the core vaccines.

Canine Parainfluenza Virus and Bordetella bronchiseptica

These are both agents associated with kennel cough in dogs. For Bordetella bronchiseptica, intranasal vaccination with live avirulent bacteria is recommended for dogs expected to board, be shown, or to enter a kennel situation within 6 months of the time of vaccination. We currently stock the intranasal vaccine containing both B. bronchiseptica and CPiV. For puppies and previously unvaccinated dogs, only one dose of this vaccine is required (recommendations differ for the parenteral, killed form of this vaccine). Most boarding kennels require that this vaccine be given within 6 months of boarding; the vaccine should be administered at least one week prior to the anticipated boarding date for maximum effect.

Canine Influenza Virus (CIV)

Canine influenza virus (H3N8) emerged in the United States in greyhounds in Florida in 2003. The virus is now enzootic in many dog populations in Colorado, Florida, Pennsylvania, New Jersey and New York. The virus causes upper respiratory signs including a cough, nasal discharge, and a low-grade fever followed by recovery. A small percentage of dogs develop more severe signs in association with hemorrhagic pneumonia. A vaccine is commercially available, which at the time of writing has a 1-year conditional licensure. Based on evidence provided by the manufacturer, the vaccine may reduce clinical signs and virus shedding in dogs infected by CIV. It may be useful for dogs traveling and intermingling with other dog populations in areas where the virus is enzootic. The performance of the vaccine and its duration of immunity in the field are unknown. At the time of writing, only a few cases of CIV infection have been documented in northern California and the infection has not been widely documented in the general dog population, so we do not recommend routine vaccination for dogs expected to board, be shown, or enter a kennel situation within northern California. Vaccination may have the potential to interfere with the results of serological testing, which in non-endemic areas are useful to assist diagnosis. The UC Davis VMTH does not stock the CIV vaccine or recommend it for use in dogs residing solely in northern California.

Canine Distemper-Measles Combination Vaccine

This vaccine has been used between 4 and 12 weeks of age to protect dogs against distemper in the face of maternal antibodies directed at CDV. Protection occurs within 72 hours of vaccination. It is indicated only for use in households/kennels/shelters where CDV is a recognized problem. Only one dose of the vaccine should be given, after which pups are boostered with the CDV vaccine to minimize the transfer of anti-measles virus maternal antibodies to pups of the next generation. The AAHA Canine Vaccination Guidelines state that 'recent unpublished studies have shown that the recombinant CDV vaccine immunizes puppies in the face of passively acquired maternal antibodies. Therefore, the distemper-measles vaccine is no longer the preferred option'. The UC Davis VMTH does not stock these vaccines as situations requiring their use do not arise commonly in our hospital population.

Canine Leptospira Vaccines

Multiple leptospiral serovars are capable of causing disease in dogs, and minimal cross-protection is induced by each serovar. Currently available vaccines do not contain all serovars, efficacies against infection with the targeted serovar are between 50 and 75%, and duration of immunity is probably about 1 year. However, leptospirosis is not uncommon in Northern Californian dogs with exposure histories involving livestock and areas frequented by wild mammals, the disease can be fatal or have high morbidity, and also has zoonotic potential. Therefore, we suggest annual vaccination of dogs living in/visiting rural areas or areas frequented by wildlife with vaccines containing all four leptospiral serovars (grippotyphosa, pomona, canicola and icterohemorrhagiae), ideally before the rainy season, when disease incidence peaks. The initial vaccination should be followed by a booster 2-4 weeks later, and the first vaccine be given no earlier than 12 weeks of age. In general, leptospiral vaccines have been associated with more severe postvaccinal reactions (acute anaphylaxis) than other vaccines. Whether the recent introduction of vaccines with reduced amounts of foreign protein has reduced this problem is still unclear. Vaccination of dogs in suburban areas with minimal exposure to farm animals or forested areas is not recommended. Anecdotally, the incidence of reactions has been greatest in puppies (< 12 weeks of age, and especially < 9 weeks of age) and small-breed dogs. A careful risk-benefit analysis is recommended before considering vaccination of small breed dogs at risk of exposure to leptospires.

Canine Borrelia burgdorferi (Lyme) Vaccine

The incidence of Lyme disease in California is currently considered extremely low. Furthermore, use of the vaccine even in endemic areas (such as the east coast of the US) has been controversial because of anecdotal reports of vaccine-associated adverse events. Most infected dogs show no clinical signs, and the majority of dogs contracting Lyme disease respond to treatment with antimicrobials. Furthermore, prophylaxis may be effectively achieved by preventing exposure to the tick vector. If travel to endemic areas (ie the east coast) is anticipated, vaccination with the Lyme subunit or OspC/OspA-containing bivalent bacterin vaccine could be considered, followed by boosters at intervals in line with risk of exposure. The UC Davis VMTH does not stock the Lyme vaccine or recommend it for use in dogs residing solely in northern California.

Other Canine Vaccines

Several other canine vaccines are currently available on the market. These are vaccines for canine coronavirus, Giardia spp., canine adenovirus-1, rattlesnake envenomation, and Porphyromonas vaccine. The reports of the AVMA and the AAHA canine vaccine task force have listed the first three vaccines as not generally recommended, because 'the diseases are either of little clinical significance or respond readily to treatment', evidence for efficacy of these vaccines is minimal, and they may 'produce adverse events with limited benefit'. Currently, information regarding the efficacy of the canine rattlesnake and Porphyromonas vaccines is insufficient. The UC Davis VMTH does not stock or routinely recommend use of these four vaccines.

Canine Coronavirus Vaccine

Infection with canine enteric coronavirus (CCV) alone has been associated with mild disease only, and only in dogs < 6 weeks of age. It has not been possible to reproduce the infection experimentally, unless immunosuppressive doses of glucocorticoids are administered. Serum antibodies do not correlate with resistance to infection, and duration of immunity is unknown. In mixed infections with CCV and canine parvovirus (CPV), CPV is the major pathogen. Vaccination against CPV therefore protects puppies from disease following simultaneous infection with both canine enteric coronavirus and CPV. Thus, the UC Davis VMTH does not routinely recommend vaccination against canine enteric coronavirus and the vaccine is not stocked by our pharmacy.

Canine Giardia spp. Vaccine

Approximately 90% of dogs respond to treatment for Giardia infection, most infected dogs are asymptomatic, and the disease is not usually life-threatening. The vaccine does not prevent infection but may reduce shedding and clinical signs. The zoonotic potential of Giardia remains unclear. Based on existing evidence, the UC Davis VMTH does not currently recommend routine vaccination of dogs for Giardia spp, and the vaccine is not stocked by our pharmacy.

Canine Rattlesnake Vaccine

The canine rattlesnake vaccine comprises venom components from Crotalus atrox (western diamondback). Although a rattlesnake vaccine may be potentially useful for dogs that frequently encounter rattlesnakes, currently we are unable to recommend this vaccine because of insufficient information regarding the efficacy of the vaccine in dogs. Dogs develop neutralizing antibody titers to C. atrox venom, and may also develop antibody titers to components of other rattlesnake venoms, but research in this area is ongoing. Owners of vaccinated dogs must still seek veterinary care immediately in the event of a bite, because 1) the type of snake is often unknown; 2) antibody titers may be overwhelmed in the face of severe envenomation, and 3) an individual dog may lack sufficient protection depending on its response to the vaccine and the time elapsed since vaccination. According to the manufacturer, to date, rare vaccinated dogs have died following a bite when there were substantial delays (12-24 hours) in seeking treatment. Recommendations for booster vaccination are still under development, but it appears that adequate titers do not persist beyond one year after vaccination. Adverse reactions appear to be low and consistent with those resulting from vaccination with other products available on the market. The product license is currently conditional as efficacy and potency have not been fully demonstrated. Based on existing evidence, the UC Davis VMTH does not currently recommend routine vaccination of dogs for rattlesnake envenomation, and the vaccine is not stocked by our pharmacy.

Canine Porphyromonas Vaccine

The canine Porphyromonas vaccine is an inactivated Porphyromonas denticanis, P. gulae and P. salivosa bacterin. It has been marketed 'as an adjunct to professional dental cleaning, periodontal therapy, and owner-administrated dental care routines' to prevent periodontitis, as demonstrated by a reduction in bone changes (bone loss/sclerosis) in mice used as an experimental model. The manufacturer recommends that primary vaccination consist of 2 doses given subcutaneously 3 weeks apart. The product license is currently conditional as efficacy and potency have not been demonstrated in dogs. Based on existing evidence, the UC Davis VMTH does not currently recommend routine vaccination of dogs for periodontal disease with this vaccine, and the vaccine is not stocked by our pharmacy.

Feline Vaccination Guidelines

In general, guidelines for vaccination of cats have been strongly influenced by the appearance of vaccine-associated sarcomas in cats, and in particular their epidemiologic association with feline leukemia virus vaccines and killed rabies virus vaccines. Thus, there is clear evidence for minimizing frequency of vaccination in cats. The recommendations below have been made in light of the AVMA/AAHA/AAFP/VCS task force recommendations on vaccine-associated sarcomas in cats. Risk factors for sarcomas should be discussed with cat owners at the time of examination. If a cat develops a palpable granuloma at the site of previous vaccination, the benefits vs risks of future vaccinations should be carefully considered. All vaccine-associated sarcomas should be reported to the vaccine manufacturer, the USDA Center for Veterinary Biologics, and the AVMA.

Feline Core Vaccines

The definitions of core and non-core vaccines described in the canine vaccination guidelines above also apply to the feline vaccines. The core feline vaccines are those for feline herpesvirus 1 (FHV1), feline calicivirus (FCV), feline panleukopenia virus (FPV) and rabies.

Feline Herpesvirus 1, Feline Calicivirus and Feline Panleukopenia Virus Vaccines

For initial kitten vaccination (<16 weeks), one dose of parenteral vaccine containing modified live virus (MLV) FHV1, FCV, and FPV is recommended every 3-4 weeks from 6-8 weeks of age, with the final booster being given no sooner than 16 weeks of age. For cats older than 16 weeks of age, two doses of vaccine containing modified live virus (MLV) FHV1, FCV, and FPV given 3-4 weeks apart are recommended. After a booster at one year, revaccination is suggested every 3 years thereafter for cats at low risk of exposure. According to recommendations of the vaccine-associated sarcoma task force, these vaccines are administered over the right shoulder. Note that recommendations for killed and intranasal FHV1 and FCV vaccines are different from the above. Killed and intranasal varieties of these vaccines are not routinely used at the VMTH. The use of FPV MLV vaccines should be avoided in pregnant queens and kittens less than one month of age.

Feline Rabies Virus Vaccines

Cats are important in the epidemiology of rabies in the US. In general we recommend that kittens receive a single dose of killed or recombinant rabies vaccine at 12-16 weeks of age. Adult cats with unknown vaccination history should also receive a single dose of killed or recombinant rabies vaccine. For the recombinant vaccines, boosters are recommended at yearly intervals. We currently stock and suggest the use of the recombinant rabies vaccine, although there is no evidence as yet that it is associated with a decreased risk of sarcoma formation. For the killed rabies vaccines, a booster is required at one year, and thereafter, rabies vaccination should be performed every 3 years using a vaccine approved for 3-year administration. According to recommendations of the vaccine-associated sarcoma task force, rabies vaccines are administered subcutaneously as distally as possible in the right rear limb.

Feline Non-Core Vaccines

Optional or non-core vaccines for cats consist of the vaccines for feline leukemia virus (FeLV), feline immunodeficiency virus, virulent FCV, Chlamydophila felis, and Bordetella bronchiseptica.

Feline Leukemia Virus Vaccine

A number of FeLV vaccines are available on the market. The whole inactivated viral vaccines have recently been shown to be highly efficacious based on the results of molecular detection methods for FeLV, even producing sterilizing immunity, although this was not found to be the case for a inactivated mixed subunit vaccine (Torres et al, 2009). We recommend vaccination of FeLV-negative cats allowed to go outdoors or cats having direct contact with other cats of unknown FeLV status. Vaccination is most likely to be useful in kittens and young adult cats, because acquired resistance to infection develops beyond 16 weeks of age. As of 2006, the AAFP recommends primary vaccination of all kittens for FeLV, but the decision to administer booster vaccines is based on risk assessment. Vaccination is not recommended for FeLV-positive cats and indoor cats with no likelihood of exposure to FeLV.

Because of concerns relating to sarcoma formation following administration of killed, adjuvanted vaccines, we currently stock and suggest the use of the recombinant transdermal FeLV vaccine. This vaccine does not produce chronic inflammatory reactions, which are a prerequisite for sarcoma induction. Its efficacy has been demonstrated only using commonly used antigen detection methods, and not highly sensitive nucleic acid detection methods. Therefore, it is uncertain whether immunity is of priming or sterilizing nature.

Initially, two doses of FeLV vaccine are given at 2-4 week intervals, after which annual boosters are recommended depending on risk. According to recommendations of the vaccine-associated sarcoma task force, parenteral FeLV vaccines are administered subcutaneously as distally as possible in the left rear limb.

Feline Immunodeficiency Virus Vaccine

The FIV vaccine is an inactivated, adjuvented dual subtype vaccine that was released in July 2002. Unfortunately, vaccination of FIV-negative cats renders currently available serologic tests (ELISA and Western blot) positive for at least a year following vaccination, and polymerase chain reaction (PCR)-based tests do not reliably identify cats with natural infection. Previous vaccination does not prevent infection, and the significance of a positive test result in a vaccinated cat cannot be assessed. Questions remain regarding the vaccine's ability to protect against all of the FIV subtypes and strains to which cats might be exposed. Therefore, the decision regarding whether to use this vaccine is not straightforward, and the risks and benefits of the use of this vaccine should be carefully discussed with owners prior to using the vaccine in cats at risk of exposure. The UC Davis VMTH pharmacy does not stock this vaccine, and its routine use in indoor cats is not recommended.

Virulent Calicivirus Vaccine

The virulent FCV vaccine (Calicivax) is a killed, adjuvanted vaccine containing just one of many different strains of hypervirulent FCV known to cause severe systemic disease, including facial or limb edema, cutaneous ulceration, hepatocellular dysfunction, and high mortality. The disease is relatively rare, but has often involved otherwise healthy, adult cats that have been vaccinated with core vaccines containing FCV. In general, outbreaks have been self-limiting with no spread to the wider cat community. Although the virulent FCV vaccine has protected against challenge with the same FCV strain present in the vaccine, no field studies have yet been performed to determine whether it protects against other virulent strains. Given that the degree of serologic cross-reactivity between these strains is low, cross-protection does not seem very likely. Currently we do not recommend or stock this vaccine because 1) it is an adjuvanted vaccine that may increase risk of sarcoma formation; 2) the disease is rare and spread tends to be self-limiting; and 3) the degree of cross-protection between the strain included in the vaccine and other virulent FCV strains is unknown. For more information on this disease, the reader is referred to the Center for Companion Animal Health's Shelter Medicine document.

Feline Chlamydophila felis Vaccine

Chlamydophila felis causes conjunctivitis in cats that generally responds readily to antimicrobial treatment. Immunity induced by vaccination is probably of short duration and the vaccine provides only incomplete protection. The use of this vaccine could be considered for cats entering a population of cats where infection is known to be endemic. However, the vaccine has been associated with adverse reactions in 3% of vaccinated cats, and we do not recommend routine vaccination of low-risk cats with this vaccine. The C. felis vaccine is therefore not stocked by the VMTH pharmacy.

Feline Bordetella bronchiseptica Vaccine

This is a modified live intranasal vaccine. Bordetella bronchiseptica is primarily a problem of very young kittens, where it can cause severe lower respiratory tract disease. It appears to be uncommon in adult cats and pet cats in general. For these reasons, the UC Davis VMTH does not recommend routine vaccination of pet cats for Bordetella bronchiseptica. The vaccine could be considered for young cats at high risk of exposure in large, multiple cat environments. The UC Davis VMTH pharmacy does not stock this vaccine.

Other Feline Vaccines

Feline vaccines that have been listed as 'Not Generally Recommended' by the AAFP, include the feline infectious peritonitis (FIP) vaccine and the feline Giardia lamblia vaccine, which at the time of writing is of questionable availability.

Feline Infectious Peritonitis Vaccine

The FIP vaccine is an intranasal modified live virus product. The efficacy of this vaccine is controversial, and duration of immunity may be short, although the vaccine appears to be safe. Although exposure to feline coronaviruses in cat populations is high, the incidence of FIP is very low, especially in single-cat households (where it is 1 in 5000). Most cats in cattery situations where FIP is a problem become infected with coronaviruses prior to 16 weeks of age, which is the age at which vaccination is first recommended. Vaccination could be considered for seronegative cats entering a cattery where FIP is common. We do not routinely recommend vaccinating household cats with the FIP vaccine, and the vaccine is not stocked by our pharmacy.

Feline Giardia Vaccine

A killed Giardia vaccine has been marketed for use in cats. This vaccine has the same limitations as those listed above for canine giardiasis, and has the additional potential to induce vaccine-associated sarcomas. We currently do not recommend routine use of this vaccine in pet cats. The UC Davis VMTH pharmacy does not stock this vaccine.

Vaccination Schedules for Dogs and Puppies

Vaccines are now being divided into two classes. 'Core' vaccines for dogs are those that should be given to every dog. 'Noncore' vaccines are recommended only for certain dogs. Whether to vaccinate with noncore vaccines depends upon a number of things including the age, breed, and health status of the dog, the potential exposure of the dog to an animal that has the disease, the type of vaccine and how common the disease is in the geographical area where the dog lives or may visit.

The AVMA Council on Biologic and Therapeutic Agents' Report on Cat and Dog Vaccines has recommended that the core vaccines for dogs include distemper, canine adenovirus-2 (hepatitis and respiratory disease), canine parvovirus-2and rabies.

Noncore vaccines include leptospirosis, coronavirus, canine parainfluenza and Bordetella bronchiseptica (both are causes of 'kennel cough'), and Borrelia burgdorferi (causes Lyme Disease). Consult with your veterinarian to select the proper vaccines for your dog or puppy.

AVMA Vaccination Recommendations for Dogs

Vaccination Recommendations for Dogs

Component	Class	Efficacy	Length of Immunity	Risk/Severity of Adverse Effects	Comments
Canine Distemper	Core	High	> 1 year formodified live virus (MLV) vaccines	Low
Measles	Noncore	High in preventing disease, but not in preventing infection	Long	Infrequent	Use in high risk environments for canine distemper in puppies 4-10 weeks of age
Parvovirus	Core	High	> 1 year	Low
Hepatitis	Core	High	> 1 year	Low	Only use canine adenovirus-2 (CAV-2) vaccines
Rabies	Core	High	Dependent upon type of vaccine	Low to moderate
Respiratory disease from canine adenovirus-2 (CAV-2)	Noncore	Not adequately studied	Short	Minimal	If vaccination warranted, boost annually or more frequently
Parainfluenza	Noncore	Intranasal MLV - Moderate Injectable MLV - Low	Moderate	Low	Only recommended for dogs in kennels, shelters, shows, or large colonies; If vaccination warranted, boost annually or more frequently
Bordetella	Noncore	Intranasal MLV - Moderate Injectable MLV - Low	Short	Low	For the most benefit, use intranasal vaccine 2 weeks prior to exposure
Leptospirosis	Noncore	Variable	Short	High	Up to 30% of dogs may not respond to vaccine
Coronavirus	Noncore	Low	Short	Low	Risk of exposure high in kennels, shelters, shows, breeding facilities
Lyme	Noncore	Appears to be limited to previously unexposed dogs; variable	Revaccinate annually	Moderate

A possible vaccination schedule for the 'average' dog is shown below.

Dog Vaccination Schedule
Age	Vaccination
5 weeks	Parvovirus: for puppies at high risk of exposure to parvo, some veterinarians recommend vaccinating at 5 weeks. Check with your veterinarian.
6 & 9 weeks	Combination vaccine* without leptospirosis.  Coronavirus: where coronavirus is a concern.
12 weeks or older	Rabies: Given by your local veterinarian (age at vaccination may vary according to local law).
12 & 15 weeks**	Combination vaccine  Leptospirosis: include leptospirosis in the combination vaccine where leptospirosis is a concern, or if traveling to an area where it occurs.  Coronavirus: where coronavirus is a concern.  Lyme: where Lyme disease is a concern or if traveling to an area where it occurs.
Adult (boosters)§	Combination vaccine  Leptospirosis: include leptospirosis in the combination vaccine where leptospirosis is a concern, or if traveling to an area where it occurs.  Coronavirus: where coronavirus is a concern.  Lyme: where Lyme disease is a concern or if traveling to an area where it occurs.  Rabies: Given by your local veterinarian (time interval between vaccinations may vary according to local law).
*A combination vaccine, often called a 5-way vaccine, usually includes adenovirus cough and hepatitis, distemper, parainfluenza, and parvovirus. Some combination vaccines may also include leptospirosis (7-way vaccines) and/or coronavirus. The inclusion of either canine adenovirus-1 or adenovirus-2 in a vaccine will protect against both adenovirus cough and hepatitis; adenovirus-2 is highly preferred. **Some puppies may need additional vaccinations against parvovirus after 15 weeks of age. Consult with your local veterinarian. § According to the American Veterinary Medical Association, dogs at low risk of disease exposure may not need to be boostered yearly for most diseases. Consult with your local veterinarian to determine the appropriate vaccination schedule for your dog. Remember, recommendations vary depending on the age, breed, and health status of the dog, the potential of the dog to be exposed to the disease, the type of vaccine, whether the dog is used for breeding, and the geographical area where the dog lives or may visit. Bordetella and parainfluenza: For complete canine cough protection, we recommend Intra-Trac II ADT. For dogs that are shown, in field trials, or are boarded, we recommend vaccination every six months with Intra-Trac II ADT.

Researchers at the Veterinary Schools at the University of Minnesota, Colorado State Univers

Researchers at the Veterinary Schools at the University of Minnesota, Colorado State University, and University of Wisconsin suggest alternating vaccinations in dogs from year to year. Instead of using multivalent vaccines (combination vaccines against more than one disease), they recommend using monovalent vaccines which only have one component, e.g., a vaccine that only contains parvovirus. So, one year your dog would be vaccinated against distemper, the next year against canine adenovirus-2, and the third year against parvovirus. Then the cycle would repeat itself. Other researchers believe we may not have enough information to recommend only vaccinating every 3 years. Manufacturers of dog vaccines have not changed their labeling which recommends annual vaccinations. Again, each dog owner must make an informed choice of when to vaccinate, and with what. Consult with your veterinarian to help you make the decision.

Core Dog Vaccinations

Young puppies are highly susceptible to certain infectious diseases and should be vaccinated against them as soon as they are old enough to build immunity. These diseases are distemper, infectious hepatitis, parvovirus, parainfluenza, and rabies.Leptospirosis, giardia, coronavirus, bordetella, bronchiseptica, and Lyme diseasevaccinations are optional, depending on the occurrence of these diseases in your area and your dog’s individual risk factors.

The American Animal Hospital Association (AAHA) has drawn up guidelines categorizing vaccines as core or noncore, and these categories will be indicated for all the vaccines described in this section. While these guidelines suggest that puppies as young as 6 weeks may be vaccinated, most veterinarians and breeders wait until 7 or 8 weeks of age. Also, vaccine recommendations state that many vaccines do not need boosters beyond 12 weeks of age, but veterinarians, particularly in endemic disease areas, may do a final puppy vaccine at about 16 weeks.

Canine Distemper (Core)

A recombinant distemper vaccine is now available and, ideally, dogs will receive either an MLV or a recombinant version of distemper vaccine.

The first distemper shot should be given shortly after weaning and before a puppy is placed in his new home and is exposed to other dogs. Some veterinarians recommend vaccinating puppies at 5 to 6 weeks of age, using a combination canine distemper-measles-parainfluenza vaccine. The rationale for combining distemper and measles vaccines is that a high percentage of 6-week-old puppies do not get a satisfactory response from the distemper vaccine alone because of maternal antibodies that neutralize the distemper antigen. The measles virus, which is quite similar to the distemper virus, can overcome maternal antibody interference and induce partial distemper protection. Alternatively, if maternal antibodies have actually disappeared in the 6-week-old puppy, the distemper portion of the vaccine will induce complete protection.

The distemper-measles vaccine should be used only once, for the first vaccination, and only in puppies. The newer recombinant distemper vaccine seems to overcome maternal antibodies and is now believed to be a better option than the distemper-measles combination.

Postvaccination encephalitis has occasionally occurred when an MLV distemper vaccine has been used in combination with a parvovirus vaccine in pups younger than 6 to 8 weeks of age. Therefore, parvovirus vaccine should not be given along with the first distemper vaccination in very young puppies. The recombinant distemper vaccine is unlikely to cause encephalitis, and is therefore recommended for young puppies.

Puppies younger than 8 to 9 weeks of age should be revaccinated every four weeks until they are 16 weeks of age. Current recommendations are to revaccinate at 1 year of age or in a year from the last vaccination, and then every three years. This time period may be extended with future research data on duration of immunity.

Infectious Hepatitis (Core)

The infectious hepatitis vaccine is a MLV vaccine containing CAV-2. This vaccine protects against canine hepatitis and two of the adenoviruses involved in the kennel cough complex (CAV-1 and CAV-2).

Hepatitis vaccine is incorporated into the DHPP shot, which is given at 8 to 12 weeks of age and again at 16 weeks of age with a possible booster in between for puppies who were initially vaccinated at 8 weeks of age or younger. It is suggested that a DHPP booster be given at 1 year of age or one year from the last vaccine. Revaccination is currently recommended every three years, although initial immunity may persist for life.

Canine Parvovirus (Core)

Commercially available vaccines effectively cross-protect against all the current strains of parvo, including variant strains. The MLV vaccine is much more effective than a killed vaccine in that it produces a faster and stronger immune response.

Because the age at which individual pups can respond to parvovirus vaccination varies, AAHA 2006 guidelines are to give the vaccine at 6 to 8 weeks of age, then every three to four weeks until the dog is 12 to 14 weeks of age, but many veterinarians prefer to wait until a puppy is 7 or 8 weeks of age to start parvo vaccinations and conclude them at 16 weeks.

High titer-low passage vaccines (see page 91) are more effective than older vaccines, even in the presence of maternal antibodies, and have narrowed the window of susceptibility that occurs between declining levels of maternal antibodies and acquired immunity produced by the vaccine. This has resulted in fewer vaccine failures.

Even after a pup has received his first series of vaccinations, he should not be exposed to dogs who may be a source of infection until after he receives his final vaccination at 16 weeks of age. Boosters are recommended every three years to maintain immunity, following an initial booster at one year. This interval may be increased with further research on vaccine efficacy.

In unvaccinated dogs older than 16 weeks, give two doses of vaccine two weeks apart. Brood bitches should be vaccinated two to four weeks before breeding to ensure high levels of antibodies in their colostrum. Some veterinarians believe this booster is unnecessary.

Rabies (Core)

The first rabies vaccination should be given at 3 to 6 months of age, with the first booster shot given one year later (at 15 months of age). Thereafter, give boosters annually or every three years, according to state and local statutes. Rabies vaccination schedules are regulated by law.